Microring YT was evaluated and compared with established methods for the identification of 142 clinical yeast isolates. Only 75 isolates (52.8%) were correctly identified by Microring YT. Results with this test were often difficult to read and subject to interlaboratory variations.
were initially cultured on Sabouraud glucose agar (CM41;
Oxoid Ltd., Basingstoke, United Kingdom) slants for 24 h at 37°C. A light suspension (equivalent to a McFarland no. 2-3 standard) of each isolate was made in sterile saline and spread over the surface of a Sabouraud's glucose agar plate with a swab. The surface was allowed to dry, and a Microring was placed in the center of the plate and pressed down gently to ensure good contact with the agar surface. Yeast identities were determined by considering a number of different features on the plates after incubation at 37°C for 24 to 48 h. Features aiding identification included the presence and the sizes of the inhibition zones around each disk on the ring and the color of the yeast growth around disk 3 (triphenyl tetrazolium chloride). Regrowth within inhibition zones, a characteristic of some yeast species, was also noted. Any inhibition zone around a disk was regarded as inhibition of growth and received a score which corresponded to the number of the disk; zones with no growth were scored as 0, and zones with regrowth were scored as the number of the disk plus the suffix R. Results were scored from 1 to 6 to yield a six-digit code (Fig. 1) . The sizes of the inhibition zones were also measured, and the identities of the yeast isolates were determined by comparing the codes, zone sizes, presence of regrowth, and color around disk 3 with a list of identification codes supplied with the Micro- was also difficult by Microring YT. None of the three isolates of C. guilliermondii were correctly identified in all three laboratories.
Interlaboratory variations in yeast identities with Microring YT were apparent, as were variations when the same batch of plates was read by more than one person. Some yeast species were incorrectly identified by Microring YT because the profiles obtained corresponded to those of another yeast species. Other isolates were not identifiable from the Microring YT profiles obtained; some isolates yielded profiles which were not present ini the data base, whereas others yielded profiles whose zone sizes did not match those in the data base.
Of the 426 profiles obtained by the three laboratories for Cryptococcus albidus (1) 1 Trichosporon beigelii (7) 7 Blastoschizomyces capitatus (4) 4 Of the yeast species which were incorrectly identified, the most common confusions existed between C. guilliermondii and Torulopsis candida, Torulopsis glabrata, and Saccharomyces cerevisiae and between Candida tropicalis and Candida pseudotropicalis. The data base used in this study did not contain profiles for the genus Trichosporon. The Trichosporon beigelii and Blastoschizomyces capitatus isolates which were incorrectly identified yielded profiles corresponding to those for C. albicans. These were the only isolates which were falsely identified as C. albicans. There was no particular pattern for the other species which were incorrectly identified.
Although the Microring YT for yeast identification is simple to use and relatively inexpensive, this preliminary study suggests that accurate identification of medically important yeast species by this method is difficult. Interpretation of the plates is often subject to reader variations, and in some cases problems exist in determining what constitutes an inhibition zone. Most isolates which were difficult to identify by Microring YT were easy to identify by established procedures of assimilation and fermentation and by API 20C AUX. The usefulness of the test is limited by the small number of yeast species included in the data base. The data base used in this study included profiles for only 18 yeast species. Although the data base can be expanded, it seems unlikely that the other problem, namely, reproducibility among laboratories and individuals, can be overcome satisfactorily.
Letters to the Editor Pathogenicity of Blastocystis hominis
We noted with interest the letters by Rosenblatt (4) and Zierdt (6) concerning the possible pathogenicity of Blastocystis hominis. This discussion is particularly exciting to the microscopist, as B. hominis is probably the second most frequently identified organism (yeasts being the first) in the gut flora. We are concerned that all laboratories are not dealing with the same set of "facts" concerning B. hominis since reports on its prevalence of have varied from 0 (5) to 3.2 (2) to 17.5 (3) %. This may be due in part to differing proficiencies of technologists at recognizing the organism.
When B. hominis was first defined (as an artifact or yeast), the abilities of laboratorians to recognize it varied highly. B. hominis was frequently included in the artifact section of atlases (1) , was never included on proficiency tests, and was hardly ever reported. In recent years it has been included, initially as an optional and then as a required organism, in CAP and other state and national survey samples. The recent review by Zierdt (7) , however, may be the first publication of extensive high-quality photographs of the organism in its various forms and stages. In our experience it is difficult for the untrained microscopist to identify B. hominis with the simple hematology microscope frequently employed for parasite examinations. The frequency of identification improves dramatically when a microscope with high quality optics is employed. Since the organisms lack a cell wall and the cytoplasm is frequently condensed around the periphery, we employ phase-contrast optics as part of every examination. Additionally, we examine all specimens with a trichrome procedure and have found this stain to be excellent for recognition of B. hominis.
Using these procedures we have identified B. hominis with great frequency. At Meadowlands Clinical Laboratory (Rutherford, N.J.), we found an almost 20% positive rate. At Great Smokies Diagnostic Laboratory we found a 15 to 20% positive rate. As both labs are reference laboratories, receiving most of their specimens from patients visiting physician offices, the prevailing complaints are more chronic than acute. In a separate study of patients with acute gastrointestinal complaints from a largely immigrant population (62% Latin American and 23% Asian) visiting the outpatient GI Clinic of Elmhurst Hospital (Bronx, N.Y.), we observed a positive rate of Blastocystis identification of 60% (42 of 70 patients). Trichrome smears were reread at the Centers for Disease Control in Atlanta, Georgia (100% agreement), confirming the accuracy of our observations. It appears to us that this organism is very prevalent in stool samples from both acutely and chronically ill patients and that a need for improved training programs probably exists. We believe that independent of the status of this organism's pathogenicity, its presence should always be reported. Only then will physicians and researchers have the data on which to draw conclusions concerning the organism's medical signficance.
As for the question of pathogenicity, we believe that a certain confusion exists with respect to the possible involvement of this organism in chronic compared with acute illnesses. In the case of acute illness, it is important to be able to identify a unique cause and to be able to direct therapy against this cause. The case for pathogenicity of B. hominis in acute illness, although mostly based upon epidemiological evidence, is fairly strong but not conclusive. Clearly, the dialogue and debate are not over. 
